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INTRODUCTION 
Metoprolol tartrate (MT) is a selective hydrophilic ß-
blocking agent for the treatment of mild and moderate 
hypertension and also for long term management of 
angina pectoris. MT has a oral bioavailability of only 38 
% due to extensive hepatic first-pass metabolism. In the 
blood circulating system it is in the first step 12% 
protein bound, then rapidly enters the CNS and has 
moderate lipid solubility. The metabolism of this drug is 
hepatically (primarly by CYP2D6). The metabolization 
occurs also mainly in the liver. Approximately 95% of 
the drug is excreted renally and less than 5% of the drug 
is excreted unchanged in urine.  Peak plasma 
concentrations are achieved after 2–3 hours. The half-
life of the MT is about 3.2 hours, which makes frequent 
dosing necessary to maintain the therapeutic blood 
levels of the drug for long-term treatment.
1-6
 Therefore, 
MT is an ideal drug candidate for transdermal drug 
delivery. Several methods have been reported for 
quantification of MT in plasma using high-performance 
liquid chromatography (HPLC) with UV or 
fluorescence detection. Many of these methods involve 
a complex separation step and are non-reproducible. 
Hence, the purpose of this investigation was to develop 
a simple, sensitive, selective and reproducible analytical 
method for the quantitative estimation of MT in a small 
volume of human plasma. It is also envisaged that this 
method will be able to provide an efficient solution for 
pharmacokinetic, bioavailability or bioequivalence 
studies of MT. This work is performed to ascertain the 
comparative bioavailability of MT from oral and 
transdermal dosage forms.
1,7-10
 
EXPERIMENTAL 
Methodology 
In the present work a simple, selective, rapid, precise 
and economical reverse phase HPLC method have been 
developed for estimation of Metoprolol tatrate in blood 
plasma. 
Table 1: Solubility of Drug in Different Solvents 
SOLVENT      SOLUBILITY 
Water Freely soluble 
0.1N HCl soluble 
0.1N NaoH  Insoluble 
Methanol Freely soluble 
Acetonitrile Soluble 
Acetate Buffer Soluble 
Phosphate Buffer Soluble 
 
ABSTRACT 
A simple, specific, sensitive and rapid Reverse phase high performance liquid chromatographic (RP-HPLC) method has been 
developed and validated for the quantification of Metoprolol Tartrate in small volumes of rabbit plasma. The method was 
further extended for its pharmacokinetic studies in rabbit plasma samples after transdermal and oral administration. Biological 
sample preparation involving simple extraction with organic solvent, followed by dilution with mobile phase was adopted to 
eliminate any chromatographic solvent effects. The method was proven to be linear over a plasma concentration range of 20 
ng/ml to100 ng/ml with a mean correlation coefficient of 0.99. The limit of detection and the limit of quantification of the 
newly developed method were determined to be 5.8ng/mL and 16.1ng/mL, respectively. The method was successfully applied 
to assess pharmacokinetic parameters of Metoprolol Tartrate in rabbit plasma and found out the comparative bioavailability of 
MT following oral and transdermal dosage forms. The developed method was established as a rapid analytical tool in a 
pharmacokinetic study as it required short retention time, high precision, sensitivity and small volumes of plasma for analysis. 
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Solubility
1-2
 
Solubility of all three drugs was observed by dissolving 
them in different solvents. (Table 1) 
 Selection of Precipitating Agent
12,13
  
Selection of precipitation agent is based on the 
solubility of drug and good protein protein precipitation 
property. Metoprolol tartrate is soluble in Acetonitrile 
and having good protein precipitating property so 
Acetonitrile was selected as the protein precipitation 
agent. 
Selection of Mobile Phase
9-13
 
Initially to estimate Metoprolol tartrate, numbers of 
mobile phase in different ratio were tried. A result was 
shown in (Table 2).  
Taking into consideration the system suitability 
parameter like RT, Tailing factor, No. of theoretical 
plates and HETP, the mobile phase found to be most 
suitable for analysis was Acetonitrile: Methanol: 20 
mM Ammonium acetate buffer (pH 5.0) in the ratio of 
25:55:20 v/v/v. The mobile phase was filtered through 
0.45 filter paper to remove particulate matter and then 
degassed by sonication. Flow rate employed for 
analysis was 1.0 ml/min.        
  
Table 2: Mobile Phase Selection 
Mobile Phase Ratio Flow rate Remark 
Methanol : water 50 : 50 v/v 1.0 ml/min Peak Not Found 
Acetonitrile : water 50 : 50 v/v 1.0 ml/min Peak Not Found 
Methanol : Acetonitrile 50: 50 v/v 1.0 ml/min Peak Not Found 
20 mM KH2PO4 : Acetonitrile (pH Adjust with 4.0 with OPA) 20 : 80 v/v 1.0 ml/min Poor resolution 
20 mM KH2PO4 : Acetonitrile (pH Adjust with 3.5 with OPA) 30 : 70 v/v 1.0 ml/min Poor resolution 
20 mM Ammonium acetate buffer (pH 5.0) 25: 55: 20 v/v/v 1.0 ml/min Satisfactory 
Result 
 
 Procedure for preparation of mobile phase 
Step-1 preparation of buffer 
20 mM Ammonium acetate Buffer in 1000 ml of HPLC 
grade water, sonicated and pH adjusted to 5 with 
orthophosphoric acid.  
Step-2 preparation of mobile phase 
Mixed 55 volume of acetonitrile, 25 volume of 
methanol and 20 volume of buffer. Filtered through 
0.45  nylon filter in Millipore unit and degassed by 
sonication.  
Selection of Diluent 
Diluent used for preparation of sample were compatible 
with mobile phase and no significant effect was 
observed for retention and resolution of analyte. After 
various trials Acetonitrile: Methanol: 20 mM 
Ammonium acetate buffer (pH 5.0) was used as 
diluents.
 
Selection of Separation Variable 
Table 3: Separation Variable 
Variable Condition 
Column  
Dimension. 250mm x 4.60mm 
Particle Size 5 
Bonded Phase Octadecylsilane (C18) 
Mobile Phase  
Acetonitril 25% 
Methanol 55% 
Phosphate buffer ( pH- 5.0) 20% 
Diluent ACN: Methanol: 20mM Ammonium 
Acetate Buffer pH-5.0 (25:55:20 v/v/v) 
Flow rate 1.0 ml/min 
Temperature 25 
0
C 
Sample Size 20 l 
Detection wavelength 274 nm 
Retention time 10.792 ± 0.001 min 
 
1. Preparation of stock solution: Accurately weighed 
10 mg of MT was transferred into 50 ml volumetric 
flasks separately and dissolved in 10 ml of plasma, then 
volume was made up to 50 ml with Acetonitrile and 
vortex it to get complete precipitation of plasma protein. 
Stand it aside for few minute, precipitate of protein 
Bhowmick et al                                      Journal of Drug Delivery & Therapeutics. 2015; 5(4):43-53 45 
© 2011-15, JDDT. All Rights Reserved                                                   ISSN: 2250-1177                                             CODEN (USA): JDDTAO 
settled down then collect the supernatant layer. 
Centrifuge the collected supernatant layer at 6000 rpm 
for 7 min at 4
o
C and then filtered by whatmann filter 
paper (no.41). Concentration of MT was 200 
µg/ml(stock- A). 
2. Preparation of Sub Stock Solution: 5 ml of solution 
was taken from stock-A of METO and transferred into 
100 ml volumetric flask separately and diluted up to 
100 ml with diluent (Mobile phase) to give 
concentration of 10 µg/ml (Stock-B). 
3. Linearity and Calibration Graph: 
To establish the linearity of analytical method, a series 
of dilution ranging from 20-100 ng/ml was prepared. 
0.2ml, 0.4 ml, 0.6ml, 0.8ml and 1.0ml of stock-B was 
taken separately in 10 ml volumetric flask and volume 
was made up to 100ml with (Acetonitrile: Methanol: 
Ammonium acetate buffer (pH 5.0). This gives the 
solutions of 20ng/ml, 40ng/ml, 60ng/ml, 80ng/ml, 
100ng/ml for drug. 
All the solution were filtered through 0.2m membrane 
filter and injected, chromatograms were recorded at 
274nm and it was repeated for six times. A calibration 
graph was plotted between the mean peak area and 
respective concentration and regression equation was 
derived. 
Fabrication of Drug loaded transdermal films
14-
17,20,23,24
: 
The Drug loaded monolithic matrix type transdermal 
patches were prepared by film casting technique on 
mercury substrate using different ratios of 
ERLPO:Methocel K15M, ERSPO:Methocel K15M, 
Acrylcoat S100:Methocel K15M and Acrylcoat 
L100:Methocel K15M (1:4,2:3,3:2,4:1) containing drug 
Metoprolol Tartrate (15.92 mg/ square centimeter 
patch).  The polymers were weighed in requisite ratios 
keeping the total polymer weight 500 mg. Hydrophilic 
materials i.e. Methocel K15M was dissolved in water 
and hydrophobic materials i.e. Eudragit RLPO, Eudragit 
RLPO, Acrylcoat S100 or Acrylcoat L100 was 
dissolved in blend of dichloromethane (DCM) and 
ethanol (50:50). Then both the solution were mixed and 
stirred on magnetic stirrer to accomplished 
homogeneous mixture. The above polymeric dispersion 
was sonicated for 2 minutes to remove entrapped air 
bubbles.  In this study Lipophilic plasticizers DBP & 
DBS or hydrophilic plasticizers such as PEG 400 & 
Propylene Glycol was added for each polymer 
combination. 2 different permeation enhancers of 
Terpene class such as limonene and cineole in different 
percentage alone and in combination (2.5 w/w %, 5.0 
w/w %, 7.5 w/w % or 2.5:2.5) was added to each 
polymer combination. The resulting solution (10 ml) 
was poured in a petri dish of 9.2 cm diameter containing 
mercury. The rate  of  evaporation  of  the  solvent  was  
controlled  by placing  an  inverted  funnel  over  the  
petri  dish.  The film formation  was  noted  by  
observing  the  mercury  surface after  complete  
evaporation  of  the  solvent. Aluminium foil was used 
as backing film and wax paper as release liner (which 
could be removed before application of the patch on the 
skin) were applied to complete the TDDS. The patches 
were cut with a circular metallic die of 2 cm internal 
diameter to give an area of 3.14 cm
2 
and stored in a 
desiccator until use. 
Different formulations were designed further by adding 
2 different permeation enhancers of Terpene class such 
as limonene and cineole in different percentage alone 
and in combination.     
Percentage of Limonene used: 2.5 w/w %, 5.0 w/w % 
and 7.5 w/w %  
Percentage of Cineole used: 2.5 w/w %, 5.0 w/w % and 
7.5 w/w % 
Combination of Limonene and cineole used (%): 2.5 
w/w %:2.5 w/w % 
16 optimized films were obtained (in optimization step-
3) which were having good and acceptable permeation 
enhancing capacity across porcine skin. The above 
optimized films were obtained after considering 
permeation enhancing capacity via determination of 
steady state flux, permeation coefficient and 
enhancement factor. In all the films it was found that 
combination of permeation enhancers was more 
effective in comparison to when they were used alone. 
Hence only combination of permeation enhancers was 
used for further development of transdermal films and 
their evaluation.   
 
Table 4: Formulation of Drug loaded transdermal films EM1-EM8 
Formulation 
code 
Drug 
(mg/ square 
centimeter patch) 
Polymer combination with ratio Plasticizer 
type and 
Percentage 
Permeation Enhancer 
(%w/w of polymer) 
Limonene Cineole 
EM1 15.92 ERSPO:METHOCEL K15M(1:4) PEG 400(20%) 2.5 2.5 
EM2 15.92 ERSPO: METHOCEL K15M(2:3) PEG 400 (20%) 2.5 2.5 
EM3 15.92 ERSPO: METHOCEL K15M (3:2) DBS (25%) 2.5 2.5 
EM4 15.92 ERSPO: METHOCEL K15M (4:1) DBS (25%) 2.5 2.5 
EM5 15.92 ERLPO: METHOCEL K15M (1:4) PEG 400 (20%) 2.5 2.5 
EM6 15.92 ERLPO: METHOCEL K15M (2:3) PEG 400 (20%) 2.5 2.5 
EM7 15.92 ERLPO: METHOCEL K15M (3:2) DBS (25%) 2.5 2.5 
EM8 15.92 ERLPO: METHOCEL K15M(4:1) DBS (25%) 2.5 2.5 
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Table 5: Formulation of Drug loaded transdermal films AM1-AM8 
Formulation 
code 
Drug 
(mg/ square 
centimeter 
patch) 
Polymer combination with ratio 
Plasticizer 
type and 
Percentage 
Permeation Enhancer 
(%w/w of polymer) 
Limonene Cineole 
AM1 15.92 
ACRYLCOAT S100: 
METHOCEL K15M (1:4) 
PG (15%) 2.5 2.5 
AM2 15.92 
ACRYLCOAT S100: 
METHOCEL K15M (2:3) 
PG (15%) 2.5 2.5 
AM3 15.92 
ACRYLCOAT S100: 
METHOCEL K15M (3:2) 
PG (15%) 2.5 2.5 
AM4 15.92 
ACRYLCOAT S100: 
METHOCEL K15M (4:1) 
DBT (30%) 2.5 2.5 
AM5 15.92 
ACRYLCOAT L100: 
METHOCEL K15M (1:4) 
PG (15%) 2.5 2.5 
AM6 15.92 
ACRYLCOAT L100: 
METHOCEL K15M (2:3) 
PG (15%) 2.5 2.5 
AM7 15.92 
ACRYLCOAT L100: 
METHOCEL K15M (3:2) 
PG (15%)  2.5 2.5 
AM8 15.92 
ACRYLCOAT L100: 
METHOCEL K15M (4:1) 
DBT (30%) 2.5 2.5 
 
In vivo pharmacokinetic study in Rabbits
9.10,12-14,18-24
 
Study Procedure  
The In vivo pharmacokinetic study will be performed 
on twelve healthy male albino rabbits weighing between 
2.5 to 3.0 kg. The dose of the drug was calculated 
according to the body surface area of the animal. The 
rabbits were fasted overnight but water was allowed ad 
libitum. The rabbits were divided into three groups of 
four rabbits each. The rabbits were kept in cages with 
husk bedding. The hair of a dorsal skin surface of 
around 50.0 cm
2
 shaved and care taken to avoid skin 
damage during shaving. On the next morning Group A 
rabbits orally administered Metoprolol Tartrate 
(1.7mg/kg) 2 times with 0.5–1.0ml saline by feeding 
tube at 12 hour interval, Group B rabbits were applied 
the 1
st
 optimized medicated transdermal patch AM2 to 
the shaved skin surface of rabbit. Group C rabbits were 
applied the 2
nd
 optimized medicated transdermal path 
EM6 to the shaved skin surface of rabbit. The patches 
were placed over the skin with the help of surgical 
adhesive tape. The optimized patches were loaded with 
same amount of drug as oral. 
Sampling 
The blood samples (1.0ml) withdrawn from the 
marginal ear vein of the animals. The blood samples 
were collected at 0.0, 0.5, 1.0, 2.0, 4.0, 8.0, 12, 16, 20, 
and 24 hr and transferred into heparinized test tubes to 
prevent coagulation of blood. The devices were 
removed after 24 hr of sampling. The blood samples 
(1.0ml) will be extracted and centrifuged. The organic 
layer will be separated and evaporated under a gentle 
stream of nitrogen at 45
o
C. The residue will be 
constituted in mobile phase and aliquot injected into the 
HPLC to determine the drug concentration.
 
Ethical approval for the handling of experimental 
animals was obtained from the Institutional Animal 
Ethical Committee. 
In-Vivo Data Analysis 
The plasma concentration of Metoprolol Tartrate at 
different time intervals was subjected to 
pharmacokinetic analysis to calculate various 
parameters: maximum plasma concentration (Cmax), 
time to reach maximum concentration (Tmax), and area 
under the plasma concentration-time curve 
(AUC0→∞). The values of Cmax and Tmax were read 
directly from the arithmetic plot of time vs plasma 
concentration of Metoprolol Tartrate. The AUC was 
calculated by using the trapezoidal rule. The elimination 
rate constant (Ke) was calculated by regression analysis 
from the slope of the line, and the half-life (t1/2) was 
obtained by 0.693/Ke. 
Result and Discussion 
Mobile phase containing plasma was run through the 
column to obtain peaks for plasma at Rt 
2.568 minutes. 
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Figure 1: Chromatogram of blank plasma 
Standard Curve Graph of Metoprolol in Plasma 
A sample chromatogram of Metoprolol in plasma is 
shown in fig and Retention time for Metoprolol in 
plasma was found to be 10.792 ±0.001 minutes. 
Standard graph of Metoprolol with plasma was also 
plotted which shows a linearity range of 20 ng/ml to100 
ng/ml and regression of 0.99. The data of standard 
curve for Metoprolol in blood plasma is given in table 
and figure. 
 
 
Figure 2: Chromatogram of pure Metoprolol in blood plasma 
Table 6: Standard curve of Metoprolol in Plasma 
 
Standard 
Concentration 
ng/ml 
Area under Curve (AUC) at RT (10.792 ± 0.001 min) Mean±SD* 
Rep-1 Rep-2 Rep-3 Rep-4 Rep-5 Rep-6  
20 855.265 854.225 868.256 856.236 860.569 848.236 857.1311±6.744395 
40 1605.26 1599.27 1603.147 1612.548 1602.258 1608.589 1605.179±4.764753 
60 2415.24 2412.22 2425.16 2450.256 2415.569 2411.254 2421.617±7.660787 
80 3150.27 3147.27 3145.27 3140.548 3125.654 3150.256 3143.211±9.332913 
100 4018.26 4012.25 4020.15 4015.587 4023.547 4018.874 4018.111±3.873858 
Correl Coeff (r
2
) 0.999 0.999 0.999 0.999 0.999 0.999 0.999±0.00 
Slope (m) 39.35  39.32 39.23  39.23  39.24  39.41 39.2966±0.075829 
Intercept (c) 47.55 45.83  58.62 61.02 50.71 42.55 51.04667±7.32898 
*Standard deviation 
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Figure 3: Calibration curve of Metoprolol tartrate 
Table 7: HPLC data for pure Metoprolol in rabbit 
plasma 
Parameter  Rabbit Plasma 
Retention time (min)  10.792±0.001 
Linearity range (ng/ml)  20-100 
R
2
value 0.999 
Equation for linearity y = 39.3x + 51.05 
RSD% 0.096-0.7868 
System Suitability Parameters 
Separation variables were set and mobile phase was 
allowed to saturate the column at 1.00 ml/min. After 
complete saturation of column, six replicates of 
working standard of Metoprolol tartrate 100 ng/ml was 
injected separately. Peak report and column 
performance report were recorded for all 
chromatogram.
 
Table 8: System Suitability Parameters of Metoprolol 
System suitability 
Parameter  
RT AUC No. of theoretical 
plates 
Tailing 
factor 
HETP 
Rep-1 10.792 4018.26  2954 1.78 0.08463 
Rep-2 10.793 4012.25 2953 1.77 0.08466 
Rep-3 10.794 4020.15 2963 1.77 0.08437 
Rep-4 10.794 4015.587 2955 1.74 0.08460 
Rep-5 10.792 4023.547 2952 1.78 0.08469 
Rep-6 10.793  4018.874 2951 1.77 0.08472 
Mean 10.793  4018.111 2954.67 1.77 0.084612 
S.D.* 0.001 3.873858 4.320 0.015 0.000126 
 RSD%**  0.009265 0.09641 0.146 0.832 0.148637 
     ** % Relative Standard deviation *Standard deviation 
 
Validation of Developed Method 
A. Linearity 
Linearity of analytical procedure is its ability (within a 
given range) to obtain test, which are directly 
proportional to area of analyte in the sample. The 
calibration plot was contracted after analysis of five 
different (from 20 to 100 ng/ ml) concentrations and 
areas for each concentration was recorded five times, 
and mean area was calculated. The regression equation 
and correlation coefficient of curve are given and the 
standard calibration curve of the drug is shown in 
figure. From the mean of AUC observed and respective 
concentration value, the response ratio (response factor) 
was found by dividing the AUC with respective 
concentration (Table 9). 
 
Table 9: Response Ratio Data for Linearity of Metoprolol 
Replicates Concentration 
(ng/ml) 
Mean AUC Response Ratio 
Rep-1 20 857.131 42.85 
Rep-2 40 1605.179 40.12 
Rep-3 60 2421.617 40.36 
Rep-4 80 3143.211 39.29 
Rep-5 100 4018.111 40.18 
Mean                                                                                                         40.56 
SD                                                                                                              1.344 
%RSD                                                                                                       3.313                                                                                                                      
             ** % Relative Standard deviation *Standard deviation 
 
y = 39.3x + 51.05
R² = 0.999
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Figure 4: 3D Response Ratio Curve of Metoprolol 
tartrate 
B. Specificity 
Specificity of the method was carried out to assess 
unequivocally the analyte presence of the components 
that might be expected to be present, such as impurities, 
degradation products and matrix components.  
C. Accuracy 
Recovery studies were performed to validate the 
accuracy of developed method. To pre-analysed sample 
solution, a definite concentration of standard drug 
(80%, 100%, and 120%) was added and then its 
recovery was analyzed.  
 
Table 10: Recovery Study of Metoprolol (80% Level) 
Conc. of 
sample 
(ng/ml) 
Amt. 
Added 
(ng/ml) 
Conc. Found. (ng/ml) % conc. Found Mean 
       % conc. Rep-1 Rep-2 Rep-3 Rep-1 Rep-2 Rep-3 
20 16 16.1 15.9 16.0 100.625 99.375 100.000 100.000 
40 32 31.9 31.8 32.1 99.688 99.375 100.313 99.792 
60 48 47.8 48.1 47.9 99.583 100.208 99.792 99.861 
                                                                                                          MEAN 
                 SD 
% RSD 
99.884 
0.106 
0.106 
 
** % Relative Standard deviation *Standard deviation 
Table 11: Recovery Study of Metoprolol (100% Level) 
Conc.  
of sample 
(ng/ml) 
Amt. 
Added 
(ng/ml) 
Conc. Found. (ng/ml) % conc. Found Mean 
     %conc 
Rep-1 Rep-2 Rep-3 Rep-1 Rep-2 Rep-3 
20 20 19.8 18.8 19.2 99.000 94.000 96.000 96.333 
40 40 39.6 38.9 39.3 99.000 97.250 48.250 98.167 
60 60 59.4 58.9 59.7 99.000 98.167 99.500 98.889 
MEAN 
                  SD 
% RSD                     
97.769 
1.317 
1.347 
 
** % Relative Standard deviation *Standard deviation 
Table 12:  Recovery Study of Metoprolol (120% Level) 
Conc.  
of sample 
(ng/ml) 
Amt. 
Added 
 (ng/ml) 
Conc. Found. (ng/ml) % conc. Found Mean 
   %conc 
Rep-1 Rep-2 Rep-3 Rep-1 Rep-2 Rep-3 
20 24 24.1 23.8 23.5 100.417 99.167 97.917 99.167 
40 48 47.8 47.9 47.5 99.583 99.792 98.958 99.444 
60 72 71.5 71.8 71.5 99.306 99.722 99.306 99.444 
MEAN 
                       SD 
% RSD 
99.352 
0.160 
0.161 
 
** % Relative Standard deviation *Standard deviation 
D.  Precision 
The precision are established in three differences: 
1. Repeatability 
2. Intermediate precision 
a) Day to Day 
b) Analyst to Analyst 
0
50
100
1 2 3 4 5
Response Ratio  of Linearity
Concentration
Response Ratio
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3. Reproducibility 
1. Repeatability 
The repeatability was performed for five replicate at 
five concentrations in linearity range 20, 40, 60, 80 and 
100 ng/ml for MT indicates the precision under the 
same operating condition over short interval time. 
Results of repeatability are reported in table- 
respectively. 
 
Table 13: Repeatability of Metoprolol 
        CONC. 
REP. 
CONCENTRATION FOUND (ng/ml) MEAN 
20 40 60 80 100  
Replicate-1 20.9 39.1 60.2 80.2 98.9 
Replicate-2 21.0 39.8 59.8 79.1 100.2 
Replicate-3 20.0 38.9 59.7 81.2 100.3 
Replicate-4 20.2 36.7 58.7 78.9 97.3 
Replicate-5 20.3 37.6 59.8 78.2 97.8 
MEAN 20.48 38.42 59.64 79.52 98.9 
% MEAN 102.4 96.05 99.40 99.40 98.90 99.23 
SD 0.443 1.24 0.055 0.118 0.136 0.095 
% RSD 0.043 0.129 0.056 0.118 0.137 0.097 
** % Relative Standard deviation *Standard deviation 
2. Intermidiate Precision 
a) Day To Day Precision 
Intermediate precision was also performed within laboratory variation on different days in five replicate at five 
concentrations. Results of day to day intermediate precision for METO reported in table 14respectively. 
 Table 14: Day-To-Day Variation of Metoprolol 
       CONC. 
REP. 
CONCENTRATION FOUND (ng/ml) MEAN 
20 40 60 80 100  
 Replicate-1 20.7 40.3 57.8           76.7 96.8 
Replicate-2 19.2 40.3 59.9 78.8 99.3 
Replicate-3 19.3 38.8 58.9 75.6 99.4 
Replicate-4 19.8 35.5 55.9 78.3 99.7 
Replicate-5 17.8 39.8 58.3 79.8 93.9 
MEAN 193.6 38.94 58.16 77.84 97.82 
% MEAN 96.8 97.35 96.93333 97.3 97.82 97.241 
SD 0.105 0.202 0.149 0.168 0.248 0.174 
% RSD 0.1090 0.2073 0.1533 0.1727 0.2537 0.179 
** % Relative Standard deviation *Standard deviation 
b)  Analyst- To- Analyst Precision 
Analyst to analyst variation was performed by different analyst in five replicate at five concentrations.  
Table 15: Analyst- To-Analyst Variation of Metoprolol 
CONC. 
REP. 
CONCENTRATION FOUND (ng/ml) MEAN 
20 40 60 80 100 
 
 
Replicate-1 18.1 38.2 59.41 80.3 99.8 
Replicate-2 18.2 38.9 59.32 77.9 99.9 
Replicate-3 18.3 38.1 59.01 78.9 98.3 
Replicate-4 16.1 37.3 60.31 77.2 95.8 
Replicate-5 22.3 40.3 60.20 78.8 98.8 
MEAN 18.6 38.56 59.65 78.62 98.52 
% MEAN 93 96.4 99.41667 98.275 98.52 97.122 
SD 0.226 0.113 0.057 0.117 0.166 0.136 
% RSD 0.2431 0.1168 0.0577 0.1190 0.1688 0.141 
** % Relative Standard deviation *Standard deviation 
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3. Reproducibility 
The reproducibility was performed by chemical to chemical (use of rankem chemicals in place of merck chemicals) 
variation in five replicate at five concentrations.  
Table 16: Reproducibility of Metoprolol 
CONC. 
REP. 
CONCENTRATION FOUND (ng/ml) MEAN 
20 40 60 80 100 
 
 
Replicate-1 19.1 39.2 59.4 78.9 99.6 
Replicate-2 18.7 39.4 57.9 79.3 98.9 
Replicate-3 19.4 39.3 58.7 78.3 97.8 
Replicate-4 18.5 36.7 59.1 78.9 96.9 
Replicate-5 19.7 38.6 58.9 79.9 97.9 
MEAN 19.08 38.64 58.80 79.06 98.22 
% MEAN 95.400 96.600 98.000 98.825 98.220 97.409 
SD 0.049 0.113 0.057 0.059 0.105 0.076 
% RSD 0.052 0.117 0.058 0.060 0.107 0.078 
** % Relative Standard deviation *Standard deviation 
 
Robustness 
As per ICH norms, small, but deliberate variations in 
concentration of the mobile phase were made to check 
the method’s capacity to remain unaffected. The ratio of 
mobile phase was change from, ACN: Methanol: 
Ammonium Acetate Buffer pH- 5 (25:55:20 % V/V/V), 
to (25:54:21 % V/V/V).Results of robustness are 
reported in table-  
 
Table 17: Robustness of Metoprolol 
              CONC. 
REP. 
CONCENTRATION FOUND (ng/ml) MEAN 
20 40 60 80 100  
 Replicate-1 18.9 38.9 59.8 87.7        99.2 
Replicate-2 18.4 39.9 57.4 88.9 99.2 
Replicate-3 19.3 37.3 58.3 87.9 99.6 
Replicate-4 18.3 36.7 58.9 89.5 99.5 
Replicate-5 19.9 37.3 53.4 88.9 99.3 
MEAN 19.14 38.02 57.56 78.64 99.36 
% MEAN 95.700 95.050 95.933 98.300 99.360 96.869 
SD 0.048 0.133 0.248 0.080 0.018 0.105 
% RSD 0.050 0.140 0.259 0.081 0.018 0.110 
** % Relative Standard deviation *Standard deviation 
a.  Detection Limit and Quantitation Limit 
The LOD and LOQ of developed method was calculated based on the standard deviation of response and slope of the 
linearity curve. (Table 18) 
Table 18: LOD and LOQ of Metoprolol 
Name LOD (ng/ml) ±SD* LOQ (ng/ml) ±SD* 
Metoprolol Tartrate 5.8±0.005 16.1±0.003 
*Standard deviation 
 
Plasma Estimation of Metoprolol in Rabbits 
The plasma concentrations of MT vs. time are shown in 
Fig.  and the pharmacokinetic parameters are presented 
in Table . The Cmax and tmax after oral administration of 
MT were 94.24±0.19 ng/ml and 2.000±0.00 h, 
respectively. In case of transdermal patches, the Cmax 
(91.160±0.16 to 93.160±0.13 ng/ml) and tmax (8 h) 
values were significantly different compared to oral 
route. Measurable concentrations of the drug were 
obtained within an hour of application of the patch and 
relatively steady plasma concentration of drug was 
observed for over 24 h. The biological half-life (t1/2) of 
MT was prolonged to about 6 h (oral: 2.419±1.02 h) in 
Rabbits. 
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Table 19: Plasma Estimation of Metoprolol in Rabbits 
Time 
(hrs) 
Drug concentration in blood plasma (ng/ml) 
Pure Drug 
administered orally 
Optimized Transdermal 
film AM2* 
Optimized Transdermal film 
EM6* 
0 0 0 0 
0.5 46.21±1.23 17.73±2.31 19.15±2.26 
1 68.44±1.55 36.11±2.11 38.59±2.42 
2 94.24±1.20 45.62±2.51 48.17±2.12 
4 51.51±1.77 61.77±1.52 64.53±2.31 
6 32.11±2.31 83.82±1.44 85.33±1.71 
8 19.43±1.11 91.16±1.91 93.15±1.46 
12 5.12±1.81 90.23±1.43 91.32±1.21 
14 93.14±1.41 87.41±1.22 90.55±1.20 
18 41.25±1.09 82.52±1.81 88.13±2.51 
20 22.31±1.33 63.79±1.55 71.44±2.09 
24 8.77±2.45 41.76±1.91 44.11±2.31 
*Significant compared to MT-Oral (p<0.05); each point represents Mean±SE;n=3 
 
 
Figure 5: Plasma concentration–time profile of MT after oral and transdermal patch treatment in Rabbits  
Table 20: Pharmacokinetic parameters after oral and transdermal treatment of MT 
S.No. 
Pharmacokinetic 
parameter 
Pure metoprolol administered 
orally 
Optimized 
formulation AM2 
Optimized 
formulation EM6 
1 t1/2 (hr) 2.419±1.02 6.165±0.15* 5.970±0.13* 
2 Ke(h
−1
) 0.2864±0.003 0.112±0.002* 0.116±0.002* 
3 Tmax (hr) 2.000±0.00 8.000±0.00* 8.000±0.00* 
4 Cmax (ng/ml) 94.24±0.19 91.160±0.16* 93.160±0.13* 
5 AUC 0-t (ng/ml*h) 451.565±4.22 1726.408±4.61* 1805.513±4.35* 
6 AUC0-∞ (ng/ml*h) 469.439±4.19 2097.836±4.43* 2185.458±4.11* 
7 AUMC0-∞ (ng/ml*h
2
) 2009.104±6.03 33282.570±6.21* 34600.480±6.12* 
8 MRT (hr) 4.279±1.23 15.865±0.32* 15.832±0.41* 
All values are expressed as Mean±SE, n=3 
Cmax=Maximum concentration; tmax=Time of maximum 
concentration; Ke=Elimination rate constant; 
AUC=Area under plasma concentration–time curve; 
AUMC= Area under plasma First Moment 
concentration–time curve; t1/2=Elimination half-life; 
MRT=Mean residential time, 
*Significant compared to oral MT (p<0.05)  
 
Figure 6: Application of Optimized Transdermal 
Patches 
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CONCLUSION: 
A simple, rapid, reproducible, and sensitive HPLC 
method has been developed for analysis of MT in 
human plasma. The pharmacokinetic parameters 
obtained with transdermal patches were significantly 
(p<0.05) different from those obtained with oral 
administration. The In vivo pharmacokinetic results 
from the oral administration of drug metoprolol tartrate 
solution indicate that the drug is rapidly absorbed from 
the rabbit GI tract, whereas drugs through transdermal 
route are slowly but continuously absorbed. Though the 
rise in drug concentration was slower than oral 
administration, the drug concentration in plasma 
remained high for longer period with transdermal 
patches. The calculated pharmacokinetic parameters 
indicate that the biological half life (t1/2) of drug is 
prolonged in rabbits by transdermal application in 
comparison to oral dose. Hence, the drug administered 
through transdermal patch will remain for longer period 
of time in the body and thus exert a sustained the action. 
Moreover, the improved performance of the designed 
optimized transdermal films of drug is also reflected by 
area under the curve (AUC) measurement as no trough 
and peaks in drug plasma level was recorded. The high 
AUC values observed with the patches also indicate 
increased bioavailability of the drug, this may be due to 
bypass of the hepatic first pass effects and avoidance 
from gastric degradation. The Tmax value was 
considerably high. Maximum plasma concentration 
(Cmax) of the optimized transdermal films was found to 
be less in comparison to oral dose. The significantly 
less elimination rate constant (Ke) and high mean 
residence time (MRT) values of drug by transdermal 
application in comparison to oral dose, further supports 
the sustained action of the drug from transdermal 
patches.  
On the whole, transdermal patches of MT showed better 
in vivo effectiveness in rabbits compared to oral 
administration. This could be due to slow and 
continuous supply of drug at a desirable rate to systemic 
circulation, which could better control the hypertension 
in hypertensive subjects. 
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